BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ehrenstein MR, Wing C. The BAFFling effects of rituximab in lupus: danger ahead? Nat Rev Rheumatol. 2016;12:367-372. [PMID: 26888554 DOI: 10.1038/nrrheum.2016.18] [Cited by in Crossref: 57] [Cited by in F6Publishing: 57] [Article Influence: 9.5] [Reference Citation Analysis]
Number Citing Articles
1 Kersh AE, Feldman RJ. Autoimmune Sequelae Following Rituximab Therapy: A Review of the Literature and Potential Immunologic Mechanisms. JCR: Journal of Clinical Rheumatology 2018;24:427-35. [DOI: 10.1097/rhu.0000000000000756] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
2 Fichtner ML, Jiang R, Bourke A, Nowak RJ, O'Connor KC. Autoimmune Pathology in Myasthenia Gravis Disease Subtypes Is Governed by Divergent Mechanisms of Immunopathology. Front Immunol 2020;11:776. [PMID: 32547535 DOI: 10.3389/fimmu.2020.00776] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
3 Thai L, Le Gallou S, Robbins A, Crickx E, Fadeev T, Zhou Z, Cagnard N, Mégret J, Bole C, Weill J, Reynaud C, Mahévas M. BAFF and CD4+ T cells are major survival factors for long-lived splenic plasma cells in a B-cell–depletion context. Blood 2018;131:1545-55. [DOI: 10.1182/blood-2017-06-789578] [Cited by in Crossref: 34] [Cited by in F6Publishing: 29] [Article Influence: 8.5] [Reference Citation Analysis]
4 Md Yusof MY, Shaw D, El-Sherbiny YM, Dunn E, Rawstron AC, Emery P, Vital EM. Predicting and managing primary and secondary non-response to rituximab using B-cell biomarkers in systemic lupus erythematosus. Ann Rheum Dis 2017;76:1829-36. [PMID: 28684557 DOI: 10.1136/annrheumdis-2017-211191] [Cited by in Crossref: 48] [Cited by in F6Publishing: 41] [Article Influence: 9.6] [Reference Citation Analysis]
5 Kraaij T, Arends EJ, van Dam LS, Kamerling SWA, van Daele PLA, Bredewold OW, Ray A, Bakker JA, Scherer HU, Huizinga TJW, Rabelink TJ, van Kooten C, Teng YKO. Long-term effects of combined B-cell immunomodulation with rituximab and belimumab in severe, refractory systemic lupus erythematosus: 2-year results. Nephrol Dial Transplant 2021;36:1474-83. [PMID: 32591783 DOI: 10.1093/ndt/gfaa117] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
6 Teng YKO, Bruce IN, Diamond B, Furie RA, van Vollenhoven RF, Gordon D, Groark J, Henderson RB, Oldham M, Tak PP. Phase III, multicentre, randomised, double-blind, placebo-controlled, 104-week study of subcutaneous belimumab administered in combination with rituximab in adults with systemic lupus erythematosus (SLE): BLISS-BELIEVE study protocol. BMJ Open. 2019;9:e025687. [PMID: 30898822 DOI: 10.1136/bmjopen-2018-025687] [Cited by in Crossref: 38] [Cited by in F6Publishing: 35] [Article Influence: 12.7] [Reference Citation Analysis]
7 Chen YH, Wang XY, Jin X, Yang Z, Xu J. Rituximab Therapy for Primary Sjögren's Syndrome. Front Pharmacol 2021;12:731122. [PMID: 34539411 DOI: 10.3389/fphar.2021.731122] [Reference Citation Analysis]
8 Linsley PS, Greenbaum CJ, Rosasco M, Presnell S, Herold KC, Dufort MJ. Elevated T cell levels in peripheral blood predict poor clinical response following rituximab treatment in new-onset type 1 diabetes. Genes Immun 2019;20:293-307. [PMID: 29925930 DOI: 10.1038/s41435-018-0032-1] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 4.8] [Reference Citation Analysis]
9 Schrezenmeier E, Jayne D, Dörner T. Targeting B Cells and Plasma Cells in Glomerular Diseases: Translational Perspectives. J Am Soc Nephrol 2018;29:741-58. [PMID: 29326157 DOI: 10.1681/ASN.2017040367] [Cited by in Crossref: 20] [Cited by in F6Publishing: 11] [Article Influence: 5.0] [Reference Citation Analysis]
10 Huffaker MF, Sanda S, Chandran S, Chung SA, St Clair EW, Nepom GT, Smilek DE. Approaches to Establishing Tolerance in Immune Mediated Diseases. Front Immunol 2021;12:744804. [PMID: 34616405 DOI: 10.3389/fimmu.2021.744804] [Reference Citation Analysis]
11 Ahmed AR, Kaveri S. Reversing Autoimmunity Combination of Rituximab and Intravenous Immunoglobulin. Front Immunol 2018;9:1189. [PMID: 30072982 DOI: 10.3389/fimmu.2018.01189] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
12 Chaichian Y, Wallace DJ. Innovative Trials and New Opportunities in SLE. Rheum Dis Clin North Am 2021;47:481-99. [PMID: 34215375 DOI: 10.1016/j.rdc.2021.04.010] [Reference Citation Analysis]
13 Németh T, Mócsai A, Lowell CA. Neutrophils in animal models of autoimmune disease. Semin Immunol 2016;28:174-86. [PMID: 27067180 DOI: 10.1016/j.smim.2016.04.001] [Cited by in Crossref: 25] [Cited by in F6Publishing: 21] [Article Influence: 4.2] [Reference Citation Analysis]
14 Chiche L. Treize raisons pour ne pas cibler le lymphocyte B dans le traitement du lupus érythémateux systémique. La Revue de Médecine Interne 2019;40:207-10. [DOI: 10.1016/j.revmed.2018.05.005] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
15 Pranzatelli MR. Advances in Biomarker-Guided Therapy for Pediatric- and Adult-Onset Neuroinflammatory Disorders: Targeting Chemokines/Cytokines. Front Immunol 2018;9:557. [PMID: 29670611 DOI: 10.3389/fimmu.2018.00557] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 5.0] [Reference Citation Analysis]
16 Galanopoulos N, Christoforidou A, Bezirgiannidou Z. Lupus thrombocytopenia: pathogenesis and therapeutic implications. Mediterr J Rheumatol 2017;28:20-6. [PMID: 32185250 DOI: 10.31138/mjr.28.1.20] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.2] [Reference Citation Analysis]
17 Davis LS, Reimold AM. Research and therapeutics-traditional and emerging therapies in systemic lupus erythematosus. Rheumatology (Oxford). 2017;56:i100-i113. [PMID: 28375452 DOI: 10.1093/rheumatology/kew417] [Cited by in Crossref: 25] [Cited by in F6Publishing: 21] [Article Influence: 5.0] [Reference Citation Analysis]
18 Benfaremo D, Svegliati S, Paolini C, Agarbati S, Moroncini G. Systemic Sclerosis: From Pathophysiology to Novel Therapeutic Approaches. Biomedicines 2022;10:163. [DOI: 10.3390/biomedicines10010163] [Reference Citation Analysis]
19 Atisha-Fregoso Y, Toz B, Diamond B. Meant to B: B cells as a therapeutic target in systemic lupus erythematosus. J Clin Invest 2021;131:149095. [PMID: 34128474 DOI: 10.1172/JCI149095] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
20 Tocut M, Shoenfeld Y, Zandman-Goddard G. Systemic lupus erythematosus: an expert insight into emerging therapy agents in preclinical and early clinical development. Expert Opin Investig Drugs 2020;29:1151-62. [PMID: 32755494 DOI: 10.1080/13543784.2020.1807004] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
21 Paley MA, Strand V, Kim AH. From mechanism to therapies in systemic lupus erythematosus. Curr Opin Rheumatol. 2017;29:178-186. [PMID: 28118202 DOI: 10.1097/bor.0000000000000369] [Cited by in Crossref: 22] [Cited by in F6Publishing: 14] [Article Influence: 4.4] [Reference Citation Analysis]
22 Verstappen GM, van Nimwegen JF, Vissink A, Kroese FGM, Bootsma H. The value of rituximab treatment in primary Sjögren's syndrome. Clin Immunol 2017;182:62-71. [PMID: 28478105 DOI: 10.1016/j.clim.2017.05.002] [Cited by in Crossref: 27] [Cited by in F6Publishing: 19] [Article Influence: 5.4] [Reference Citation Analysis]
23 Poh YJ, Baptista B, D'Cruz DP. Subcutaneous and intravenous belimumab in the treatment of systemic lupus erythematosus: a review of data on subcutaneous and intravenous administration. Expert Rev Clin Immunol 2017;13:925-38. [PMID: 28847197 DOI: 10.1080/1744666X.2017.1371592] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
24 Crickx E, Weill J, Reynaud C, Mahévas M. Anti-CD20–mediated B-cell depletion in autoimmune diseases: successes, failures and future perspectives. Kidney International 2020;97:885-93. [DOI: 10.1016/j.kint.2019.12.025] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
25 Häsler J, Flajnik MF, Williams G, Walsh FS, Rutkowski JL. VNAR single-domain antibodies specific for BAFF inhibit B cell development by molecular mimicry. Mol Immunol 2016;75:28-37. [PMID: 27213814 DOI: 10.1016/j.molimm.2016.05.009] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
26 Speth F, Hinze CH, Schranz P, Miller-Wiegart E, Haefner R. Combination of rituximab and abatacept as an exit strategy for repetitive B-cell depletion in children with severe autoimmune diseases: a report of three cases. Lupus 2018;27:1996-8. [PMID: 29958501 DOI: 10.1177/0961203318783057] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
27 Bhattaram P, Muschler G, Wixler V, Lefebvre V. Inflammatory Cytokines Stabilize SOXC Transcription Factors to Mediate the Transformation of Fibroblast-Like Synoviocytes in Arthritic Disease. Arthritis Rheumatol 2018;70:371-82. [PMID: 29193895 DOI: 10.1002/art.40386] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 3.8] [Reference Citation Analysis]
28 Jones A, Muller P, Dore CJ, Ikeji F, Caverly E, Chowdhury K, Isenberg DA, Gordon C, Ehrenstein MR. Belimumab after B cell depletion therapy in patients with systemic lupus erythematosus (BEAT Lupus) protocol: a prospective multicentre, double-blind, randomised, placebo-controlled, 52-week phase II clinical trial. BMJ Open 2019;9:e032569. [PMID: 31848169 DOI: 10.1136/bmjopen-2019-032569] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 5.0] [Reference Citation Analysis]
29 Degner KR, Wilson NA, Reese SR, Parajuli S, Aziz F, Garg N, Mohamed M, Singh T, Mandelbrot DA, Panzer SE, Redfield RR, Van Hyfte K, Zhong W, Hidalgo LG, Djamali A. Short-term Immunopathological Changes Associated with Pulse Steroids/IVIG/Rituximab Therapy in Late Kidney Allograft Antibody Mediated Rejection. Kidney360 2020;1:389-98. [PMID: 34476406 DOI: 10.34067/kid.0001082019] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
30 Lee WS, Amengual O. B cells targeting therapy in the management of systemic lupus erythematosus. Immunol Med 2020;43:16-35. [PMID: 32107989 DOI: 10.1080/25785826.2019.1698929] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
31 Atisha-Fregoso Y, Malkiel S, Harris KM, Byron M, Ding L, Kanaparthi S, Barry WT, Gao W, Ryker K, Tosta P, Askanase AD, Boackle SA, Chatham WW, Kamen DL, Karp DR, Kirou KA, Sam Lim S, Marder B, McMahon M, Parikh SV, Pendergraft WF 3rd, Podoll AS, Saxena A, Wofsy D, Diamond B, Smilek DE, Aranow C, Dall'Era M. Phase II Randomized Trial of Rituximab Plus Cyclophosphamide Followed by Belimumab for the Treatment of Lupus Nephritis. Arthritis Rheumatol 2021;73:121-31. [PMID: 32755035 DOI: 10.1002/art.41466] [Cited by in Crossref: 22] [Cited by in F6Publishing: 16] [Article Influence: 11.0] [Reference Citation Analysis]
32 Boldison J, Da Rosa LC, Buckingham L, Davies J, Wen L, Wong FS. Phenotypically distinct anti-insulin B cells repopulate pancreatic islets after anti-CD20 treatment in NOD mice. Diabetologia 2019;62:2052-65. [PMID: 31444529 DOI: 10.1007/s00125-019-04974-y] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
33 Mitchell D, Shireman J, Sierra Potchanant EA, Lara-Velazquez M, Dey M. Neuroinflammation in Autoimmune Disease and Primary Brain Tumors: The Quest for Striking the Right Balance. Front Cell Neurosci 2021;15:716947. [PMID: 34483843 DOI: 10.3389/fncel.2021.716947] [Reference Citation Analysis]
34 Hobeika L, Ng L, Lee IJ. Moving Forward With Biologics in Lupus Nephritis. Adv Chronic Kidney Dis 2019;26:338-50. [PMID: 31733718 DOI: 10.1053/j.ackd.2019.08.008] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
35 Fanouriakis A, Adamichou C, Koutsoviti S, Panopoulos S, Staveri C, Klagou A, Tsalapaki C, Pantazi L, Konsta S, Mavragani CP, Dimopoulou D, Ntali S, Katsikas G, Boki KA, Vassilopoulos D, Konstantopoulou P, Liossis SN, Elezoglou A, Tektonidou M, Sidiropoulos P, Erden A, Sfikakis PP, Bertsias G, Boumpas DT. Low disease activity-irrespective of serologic status at baseline-associated with reduction of corticosteroid dose and number of flares in patients with systemic lupus erythematosus treated with belimumab: A real-life observational study. Semin Arthritis Rheum 2018;48:467-74. [PMID: 29555348 DOI: 10.1016/j.semarthrit.2018.02.014] [Cited by in Crossref: 33] [Cited by in F6Publishing: 30] [Article Influence: 8.3] [Reference Citation Analysis]
36 Tesfa D, Sander B, Lindkvist H, Nilsson C, Kimby E, Hägglund H, Wahlin BE, Klimkowska M, Palmblad J. The role of BAFF and G-CSF for rituximab-induced late-onset neutropenia (LON) in lymphomas. Med Oncol 2021;38:70. [PMID: 34003398 DOI: 10.1007/s12032-021-01516-8] [Reference Citation Analysis]
37 Lazaro E, Scherlinger M, Truchetet M, Chiche L, Schaeverbeke T, Blanco P, Richez C. Biotherapies in systemic lupus erythematosus: New targets. Joint Bone Spine 2017;84:267-74. [DOI: 10.1016/j.jbspin.2016.07.004] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.4] [Reference Citation Analysis]
38 Fava A, Petri M. Systemic lupus erythematosus: Diagnosis and clinical management. J Autoimmun. 2019;96:1-13. [PMID: 30448290 DOI: 10.1016/j.jaut.2018.11.001] [Cited by in Crossref: 110] [Cited by in F6Publishing: 89] [Article Influence: 27.5] [Reference Citation Analysis]
39 Serris A, Amoura Z, Canouï-Poitrine F, Terrier B, Hachulla E, Costedoat-Chalumeau N, Papo T, Lambotte O, Saadoun D, Hié M, Blanche P, Lioger B, Gottenberg JE, Godeau B, Michel M. Efficacy and safety of rituximab for systemic lupus erythematosus-associated immune cytopenias: A multicenter retrospective cohort study of 71 adults. Am J Hematol 2018;93:424-9. [PMID: 29247540 DOI: 10.1002/ajh.24999] [Cited by in Crossref: 29] [Cited by in F6Publishing: 27] [Article Influence: 7.3] [Reference Citation Analysis]
40 Alexander T, Cheng Q, Klotsche J, Khodadadi L, Waka A, Biesen R, Hoyer BF, Burmester GR, Radbruch A, Hiepe F. Proteasome inhibition with bortezomib induces a therapeutically relevant depletion of plasma cells in SLE but does not target their precursors. Eur J Immunol 2018;48:1573-9. [PMID: 29979809 DOI: 10.1002/eji.201847492] [Cited by in Crossref: 32] [Cited by in F6Publishing: 26] [Article Influence: 8.0] [Reference Citation Analysis]
41 Lenert A, Niewold TB, Lenert P. Spotlight on blisibimod and its potential in the treatment of systemic lupus erythematosus: evidence to date. Drug Des Devel Ther 2017;11:747-57. [PMID: 28331294 DOI: 10.2147/DDDT.S114552] [Cited by in Crossref: 17] [Cited by in F6Publishing: 10] [Article Influence: 3.4] [Reference Citation Analysis]
42 Möckel T, Basta F, Weinmann-Menke J, Schwarting A. B cell activating factor (BAFF): Structure, functions, autoimmunity and clinical implications in Systemic Lupus Erythematosus (SLE). Autoimmun Rev 2021;20:102736. [PMID: 33333233 DOI: 10.1016/j.autrev.2020.102736] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
43 Geh D, Gordon C. Epratuzumab for the treatment of systemic lupus erythematosus. Expert Rev Clin Immunol 2018;14:245-58. [PMID: 29542345 DOI: 10.1080/1744666X.2018.1450141] [Cited by in Crossref: 13] [Cited by in F6Publishing: 7] [Article Influence: 3.3] [Reference Citation Analysis]
44 Chattopadhyay A, Acharya N, Mishra D, Sharma V, Naidu G, Sharma A. 'MAINRITSAN2-the future', with some doubts! Ann Rheum Dis 2019;78:e139. [PMID: 30315002 DOI: 10.1136/annrheumdis-2018-214486] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
45 Traub J, Häusser-Kinzel S, Weber MS. Differential Effects of MS Therapeutics on B Cells-Implications for Their Use and Failure in AQP4-Positive NMOSD Patients. Int J Mol Sci 2020;21:E5021. [PMID: 32708663 DOI: 10.3390/ijms21145021] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
46 Traub J, Husseini L, Weber MS. B Cells and Antibodies as Targets of Therapeutic Intervention in Neuromyelitis Optica Spectrum Disorders. Pharmaceuticals (Basel) 2021;14:37. [PMID: 33419217 DOI: 10.3390/ph14010037] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
47 McCarthy EM, Sutton E, Nesbit S, White J, Parker B, Jayne D, Griffiths B, Isenberg DA, Rahman A, Gordon C, D'Cruz DP, Rhodes B, Lanyon P, Vital EM, Yee CS, Edwards CJ, Teh LS, Akil M, McHugh NJ, Zoma A, Bruce IN; British Isles Lupus Assessment Group Biologics Register. Short-term efficacy and safety of rituximab therapy in refractory systemic lupus erythematosus: results from the British Isles Lupus Assessment Group Biologics Register. Rheumatology (Oxford) 2018;57:470-9. [PMID: 29216396 DOI: 10.1093/rheumatology/kex395] [Cited by in Crossref: 43] [Cited by in F6Publishing: 34] [Article Influence: 10.8] [Reference Citation Analysis]
48 Oniszczuk J, Beldi-Ferchiou A, Audureau E, Azzaoui I, Molinier-Frenkel V, Frontera V, Karras A, Moktefi A, Pillebout E, Zaidan M, El Karoui K, Delfau-Larue MH, Hénique C, Ollero M, Sahali D, Mahévas M, Audard V. Circulating plasmablasts and high level of BAFF are hallmarks of minimal change nephrotic syndrome in adults. Nephrol Dial Transplant 2021;36:609-17. [PMID: 33241414 DOI: 10.1093/ndt/gfaa279] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
49 Bag-Ozbek A, Hui-Yuen JS. Emerging B-Cell Therapies in Systemic Lupus Erythematosus. Ther Clin Risk Manag 2021;17:39-54. [PMID: 33488082 DOI: 10.2147/TCRM.S252592] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
50 Petricca L, Gigante MR, Paglionico A, Costanzi S, Vischini G, Di Mario C, Varriano V, Tanti G, Tolusso B, Alivernini S, Grandaliano G, Ferraccioli G, Gremese E. Rituximab Followed by Belimumab Controls Severe Lupus Nephritis and Bullous Pemphigoid in Systemic Lupus Erythematosus Refractory to Several Combination Therapies. Front Med (Lausanne) 2020;7:553075. [PMID: 33195302 DOI: 10.3389/fmed.2020.553075] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
51 So BYF, Yap DYH, Chan TM. B Cells in Primary Membranous Nephropathy: Escape from Immune Tolerance and Implications for Patient Management. Int J Mol Sci 2021;22:13560. [PMID: 34948358 DOI: 10.3390/ijms222413560] [Reference Citation Analysis]
52 Doshi BS, Rana J, Castaman G, Shaheen MA, Kaczmarek R, Butterfield JS, Meeks SL, Leissinger C, Biswas M, Arruda VR. B cell-activating factor modulates the factor VIII immune response in hemophilia A. J Clin Invest 2021;131:142906. [PMID: 33651716 DOI: 10.1172/JCI142906] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
53 Hui-Yuen JS, Nguyen SC, Askanase AD. Targeted B cell therapies in the treatment of adult and pediatric systemic lupus erythematosus. Lupus 2016;25:1086-96. [PMID: 27497253 DOI: 10.1177/0961203316652491] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 2.4] [Reference Citation Analysis]
54 Brito-Zerón P, Retamozo S, Gheitasi H, Ramos-Casals M. Treating the Underlying Pathophysiology of Primary Sjögren Syndrome: Recent Advances and Future Prospects. Drugs 2016;76:1601-23. [PMID: 27844414 DOI: 10.1007/s40265-016-0659-z] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
55 Wakefield D, McCluskey P, Wildner G, Thurau S, Carr G, Chee SP, Forrester J, Dick A, Hudson B, Lightman S, Smith J, Tugal-Tutkun I; pre-treatment assessment Review panel. Inflammatory eye disease: Pre-treatment assessment of patients prior to commencing immunosuppressive and biologic therapy: Recommendations from an expert committee. Autoimmun Rev 2017;16:213-22. [PMID: 28137477 DOI: 10.1016/j.autrev.2017.01.003] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 3.4] [Reference Citation Analysis]
56 Xiong ZH, Cao XS, Guan HL, Zheng HL. Immunotherapies application in active stage of systemic lupus erythematosus in pregnancy: A case report and review of literature. World J Clin Cases 2020; 8(24): 6396-6407 [PMID: 33392323 DOI: 10.12998/wjcc.v8.i24.6396] [Reference Citation Analysis]
57 Henrickson SE, Ruffner MA, Kwan M. Unintended Immunological Consequences of Biologic Therapy. Curr Allergy Asthma Rep 2016;16:46. [PMID: 27324478 DOI: 10.1007/s11882-016-0624-7] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
58 Choi SC, Morel L. B cell contribution of the CD4+ T cell inflammatory phenotypes in systemic lupus erythematosus. Autoimmunity 2017;50:37-41. [PMID: 28166683 DOI: 10.1080/08916934.2017.1280028] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 1.6] [Reference Citation Analysis]
59 Kraaij T, Kamerling SWA, de Rooij ENM, van Daele PLA, Bredewold OW, Bakker JA, Bajema IM, Scherer HU, Toes REM, Huizinga TJW, Rabelink TJ, van Kooten C, Teng YKO. The NET-effect of combining rituximab with belimumab in severe systemic lupus erythematosus. J Autoimmun 2018;91:45-54. [PMID: 29636274 DOI: 10.1016/j.jaut.2018.03.003] [Cited by in Crossref: 64] [Cited by in F6Publishing: 50] [Article Influence: 16.0] [Reference Citation Analysis]